Eagle Pharmaceuticals, Inc. Accumulated Other Comprehensive Income
Eagle Pharmaceuticals, Inc. had Accumulated Other Comprehensive Income of -$1.11 million as of 2023-06-30, per its 10-Q/A filed 2023-08-09.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2023-08-09
- 2023-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.11M.
- 2023-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.11M.
- 2022-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.11M.
- 2022-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $9.38M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2023-06-30 | -$1.11M 10-Q/A · filed 2023-08-09 |
| 2023-03-31 | -$1.11M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$1.11M 10-Q/A · filed 2023-08-09 |
| 2022-09-30 | $9.38M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $2.28M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $418.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$94.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$882.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$904.00K 10-Q · filed 2021-08-09 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-08 |